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Objectives: We determined the extent, severity, distribution and type of coronary plaques in cardiac
asymptomatic patients with familial hypercholesterolemia (FH) using computed tomography (CT).
Background: FHpatients have accelerated progression of coronary artery disease (CAD)with earliermajor
adverse cardiac events. Non-invasive CT coronary angiography (CTCA) allows assessing the coronary
plaque burden in asymptomatic patients with FH.
Materials and methods: A total of 140 asymptomatic statin treated FH patients (90 men; mean age 52±8
years) underwent CT calcium scoring (Agatston) and CTCA using a Dual Source CT scanner with a clinical
follow-up of 29±8 months. The extent, severity (obstructive or non-obstructive plaque based on >50%
or <50% lumen diameter reduction), distribution and type (calciﬁed, non-calciﬁed, or mixed) of coronary
plaque were evaluated.
Results: The calcium score was 0 in 28 (21%) of the patients. In 16% of the patients there was no CT-
evidence of any CAD while 24% had obstructive disease. In total 775 plaques were detected with CT
coronary angiography, of which 11% were obstructive. Fifty four percent of all plaques were calciﬁed,
25% non-calciﬁed and 21% mixed. The CAD extent was related to gender, treated HDL-cholesterol and
treated LDL-cholesterol levels. Therewas a low incidence of cardiac events and no cardiac death occurred
during follow-up.
Conclusion: Development of CAD is accelerated in intensively treated male and female FH patients. The
extent of CAD is related to gender and cholesterol levels and ranges from absence of plaque in one out of
6 patients to extensive CAD with plaque causing >50% lumen obstruction in almost a quarter of patients
with FH.. Introduction
Familial hypercholesterolemia (FH) is an inherited autosomal
ominant disorder of the lipoproteinmetabolismwith aprevalence
f about 1 in 500 people. FH causes highly elevated serum levels of
DLcholesterolwhichmight accumulate in large andmediumsized
rteries inducing development of early coronary atherosclerosis
1].
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Cardiac CT has evolved as a safe, non-invasive imaging modal-
ity to assess coronary atherosclerosis in symptomatic [2,3] and
in asymptomatic high-risk patients [4–7]. Detection of subclinical
coronary atherosclerosis in patients with FH may provide insights
into the accelerated development of coronary artery disease (CAD)
in these asymptomatic subjects. Only few studies are available
that report about the calcium score or coronary plaque burden in
patientswith FH [8–10]. Recentlywe reported the ﬁrst results of CT
coronary angiography (CTCA) in 101 asymptomatic patients with
FH, describing the accelerated atherosclerosis in these patients
compared to patients with non anginal chest pain [11]. In this
Open access under the Elsevier OA license.present prospective cohort study of an extended patient popula-
tion of 140 asymptomatic men and women with FH, who have
been treated with high dosages of statins, we sought to eval-
uate in depth not only the CAD severity but also the extent,
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natomical distribution and plaque composition of subclinical
oronary atherosclerosis, using CT-coronary imaging. Additionally
e assessed the relation of occult CAD with patient related vari-
bles and the occurrence of adverse cardiac events and all cause
eath during the follow-up period.
. Methods and materials
.1. Study population
Between February 2008 and July 2010 we prospectively invited
14 eligible cardiac asymptomatic statin treated patients with
amilial hypercholesterolemia to participate in this study as part
f continuing recruitment of asymptomatic patients with FH.
hese patients visit the outpatient preventive clinic of the inter-
al medicine department in our hospital at least once a year for
ptimization of the medical therapy and early detection of com-
lications. All patients met the criteria for FH according to van
alst-Cohen et al. [12], which can be summarized as either (1)
he presence of a documented LDL-receptor mutation, or (2) an
DL-cholesterol level above the 95th percentile for gender and age
n combination with the presence of typical tendon xanthomas in
he patient or in a ﬁrst degree relative, or (3) an LDL-cholesterol
evel above the 95th percentile for gender and age in a ﬁrst degree
elative or proven CAD in the patient or in a ﬁrst degree relative
nder the age of 60. Patientswith secondary causes of hypercholes-
erolemia such as renal, liver, or thyroid disease were excluded. In
ddition, all participantswereasymptomatic forCAD, i.e. absenceof
ymptoms suggestive of ischemic heart disease or history of CAD.
nclusion age for women was between 45 and 70 years, for men
etween 40 and 70 years. Exclusion criteria for CTCA were renal
nsufﬁciency (serum creatinine >120mol/l) (n=4), known con-
rast allergy (n=3) and irregular heart rhythm (atrial ﬁbrillation)
n=11).
Finally 140 patients with FH could be included after written
nformed consent, 90 men and 50 women, with a mean age 52±8
ears (range 40–68 years).
The institutional Ethical Review Board approved the study pro-
ocol.
During their clinical work-up all patients were genetically
creened for a LDL-receptormutation. Lipid levelswereobtainedby
tandardmethods in patients thatwere fasting for at least 12h. The
otal cholesterol-years score (mg-y/dl) was calculated as follows:
total cholesterol level at time of FH diagnosis× age at time of diag-
osis) + (total cholesterol level after start statin treatment×years
f statin treatment) [13]. Presence of tendon xanthomas was clini-
ally evaluatedbypalpationbyexperiencedcliniciansduringyearly
linical visits to our hospital.
.2. Computed tomography coronary angiography
.2.1. Patient preparation
Patients with a heart rate above 65beats/min received an oral
ose of beta-blockers (100mg metoprolol) 1h before the scan, in
he absence of contraindications. Just prior to the scan all patients
eceived nitroglycerin (0.4mg/dose) sublingually.
.2.2. Scan protocol
All scans were performed on a Dual Source CT scanner (First
01 scans: Somatom Deﬁnition, last 39 scans: Somatom Deﬁ-
ition FLASH, Siemens Medical Solutions, Forchheim, Germany).
or the non-enhanced scan we used a prospective ECG-triggered
can protocol with a tube current of 76mAs at 70% of the RR-
nterval. Images were reconstructed with a slice thickness of 3mm
nd an increment of 1.5mm using a medium convolution kernelsis 219 (2011) 721–727
(B35f). The contrast enhanced CTCA was obtained using a retro-
spective ECG-gated scan protocol in the ﬁrst 101 patients and a
prospective ECG-triggered protocol in the last 39 patients. The
maximum tube current was 380mAs. We applied an optimized
heart rate-dependent ECG-pulsing (retrospective) or ECG-padding
(prospective) protocol with full dose during 62–75% of the RR-
interval for heart rates <65beats/min and 31–75% for heart rates
>65beats/min [14]. In addition, automated tube-current modula-
tion was applied. Tube voltage was 120kV. Pitch (mean 0.25, range
0.2–0.34) and scan time (mean 10.0 s, range 6.9–14.3 s) of the ret-
rospective ECG-gated scans varied with the heart rate. Data of the
prospective triggered scanswere acquired during 3 or 4 heart beats
dependent of the required scan length. Iodinated contrast agent
(Ultravist 370mgI/ml, Bayer Schering Pharma, Berlin, Germany),
with a scan time dependent volume (94ml (80–100ml)), was
administered at a ﬂow rate of 5.5ml/s through an antecubital vein,
followed by a saline chaser of 40ml at 5.5ml/s. CTCA datasets
were reconstructed at a slice thickness of 0.75mm, an increment
of 0.4mm, a medium-soft convolution kernel (B26) or a sharp con-
volution kernel (B46) when calciumwas present. All datasets were
sent to a dedicated workstation (MMWP, Siemens Medical Solu-
tions, Forchheim, Germany).
Themeanestimated radiationdoseper CTCA, calculatedbymul-
tiplying the dose length product (DLP) by the conversion coefﬁcient
of 0.014mSvmGy−1 cm−1 for the chest, was 7.9mSv±2.4mSv
(range 3.9–16.4mSv) [15].
2.2.3. CT analysis
Nocomplications occurredduringor after scanning andall scans
were included in the analysis. Using the non-enhanced CT scan
the calcium scorewas calculated semi-automatically. The coronary
calcium score is expressed as the Agatston score per patient.
Twoexperienced readers analyzedall CTCAscans separately and
discrepancies in their evaluations were resolved by consensus. Per
segment, using the modiﬁed AHA 17-segment model, the absence
or presence of a coronary plaquewas determined, aswas the sever-
ity of the lumennarrowing (0, >0–20%, >20–50%, >50–70%and>70%
diameter reduction). Obstructive CAD was deﬁned as plaque caus-
ing >50% lumen diameter reduction.
We assessed a clinical CAD extent score per patient based on the
severity of plaque per coronary segment. The score is the sum of
the luminal stenosis of each individual segment (0 =0%, 1≥0–20%,
2≥20–50%, 3≥50–70% or 4≥70% lumen diameter reduction). This
results in a CAD extent score ranging from 0 to a theoretical maxi-
mum of 68.
Additionally the plaque composition was classiﬁed as (1) cal-
ciﬁed: highly attenuating tissue for >70% of the plaque volume
which could be clearly separated from the contrast enhanced coro-
nary lumen, (2) non-calciﬁed: low attenuating lesions that could
be clearly separated from the coronary lumen and the surrounding
epicardial fat or myocardium and (3) mixed: containing both calci-
ﬁed and non-calciﬁed tissue. The presence of positive remodeling
(diameter at the lesion site at least 10% larger than at the refer-
ence site)was assessed in all non-calciﬁed lesions. Vessel segments
<1.5mm in diameter were excluded from analysis.
CTCA results were blinded for treating physicians and patients
which precludes treatment decisions made based on these results.
2.3. Risk scores
The Framingham risk score (according to theNECP/ATPIII report
2002 [16]) was calculated in all FH patients. In this NECP/ATPIII
report diabetes mellitus is considered an equivalent of coronary
heart disease and for this study patients with diabetes mellitus
were considered to have a 10-years risk of 20%.
sclerosis 219 (2011) 721–727 723
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Table 1
Patients characteristics.
Variable n=140
Gender (male) 90 (64%)
Age (years) 52 (8)
Riskfactors
Smokerb 40 (29%)
Hypertensionc 37 (26%)
Diabetesd 9 (6%)
CAD positive in family historye 99 (71%)
Body mass index (kg/m2) 26.6 (3.7)
Lipids (treated)
Total cholesterol (mmol/l) 5.5 (1.4)
LDL-cholesterol (mmol/l) 3.5 (1.3)
HDL-cholesterol (mmol/l) 1.4 (0.4)
Triglycerides (mmol/l) 1.5 (1.5)
Total cholesterol-years scoref (mg-years/dl) 18321 (5112)
FH related characteristics
Known genetic disorder 93 (66%)
Age at start statin use (years) 43 (10)
Duration of statin use (years) 9 (7)
Maximum untreated total cholesterol (mmol/l) 9.7 (2.4)
Tendon xanthomas 33 (24%)
Arcus cornealis 31 (22%)
Calcium Score
Total calcium scorea (Agatston) 51 (2–350)
0 28 (20%)
0–100 51 (36%)
101–400 29 (21%)
>400 32 (23%)
CT cornary angiography
Presence of cornary plaque 23 (16%)
CAD extentg 7 (3-16)
Continuous data is expressed as mean (SD) and dichotomous data as n (%).
a The calcium score and the CAD extent are expressed as median (Inter Quartile
Range). CAD, Coronary Artery Disease; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.
b Currently and/or in the past.
c Blood pressure >140/90mmHg or treatment for hypertension.
d Treatment with oral anti-diabetic medicine or insulin.
e Premature CAD in 1st degree relative.
f Score according to Hoeg et al. [13] (pre treatment cholesterol× age at start
50% lumen diameter stenosis was detected. The CAD extent score
increasedat increasingage. Inmen themedianCADextent score (10
[4–17])was signiﬁcantlyhigher than inwomen(5 [2–11];p=0.004)L.A. Neefjes et al. / Athero
.4. Follow-up
Patient ﬁles were examined for follow-up data and patients
ere approached by telephone when recent information was
acking in the ﬁles. Cardiac events (myocardial infarction, acute
oronary syndrome (ACS), stable or unstable angina pectoris (AP),
ercutaneous coronary intervention and coronary artery bypass
raft (CABG)) and (all cause) death were inventoried.
.5. Statistical analysis
Continuous variables are shown asmean [±SD] ormedian [IQR].
ategorical variables are expressed as number [frequency]. We
sed the Mann–Whitney test to compare the CAD extent between
ale and female patients, between patients without and with dia-
etes mellitus type 2 and between patients without and with a
ardiac event during follow-up time and to compare the Fram-
ngham risk score between patients without and with obstructive
AD.
The relationship between the calculated CAD extent and patient
haracteristics, cardiovascular risk factors and lipid levels was
ssessed using linear regression analysis. Variables with a univari-
te relationship (p<0.2) with the presence of obstructive coronary
AD were entered in the multivariate regression model using
ackward elimination (p<0.1). A p-value of <0.05 was considered
tatistically signiﬁcant.
Inter-observer and intra-observer agreement is described with
he  statistics. All analyses were performed using SPSS for win-
ows (version 15.0, SPSS, Chicago, USA).
. Results
.1. Baseline
The patient characteristics are shown in Table 1. A positive fam-
ly history for cardiovascular disease was reported in 71% (99/140)
f the patients, hypertension in 26% (37/140), diabetes mellitus in
% (9/140) and smoking in 29% (40/140). In 66% (93/140) of the
atients a mutation in the LDL-receptor mutation has been iden-
iﬁed. The 34% other patients were diagnosed with FH on clinical
rounds.
.2. CT analysis
.2.1. Coronary artery disease per patient
A negative calcium score was present in 20% (28/140) of our
atients. The median coronary calcium score was 51 (IQR 2–350)
Table 1). The total calcium score signiﬁcantly increased with
igher age (3 age categories, 40–49, 50–59, and 60–69 years) in
othmen(15.4 (0–287), 194 (38–488), and521 (135–1001), respec-
ively, p<0.001) andwomen (0 (0–4), 32 (8–136), and 96 (51–662),
espectively, p<0.001).
CTCA showed no plaques in 16% (23/140) of the patients. In 60%
84/140) of the patients only lesions causing <50% lumen obstruc-
ion were present and in 24% (33/140) one or more lesions of >50%
umen diameter stenosis were detected. Four patients had obstruc-
ive lesions in all three coronaries (3-vessel disease), 9 in 2 vessels
nd 20 in 1 vessel. Presence and severity of CAD per patient (no
AD, non-obstructive CAD and obstructive CAD) was signiﬁcantly
igher in patients at higher age in men (p=0.03) and in women
p=0.01).
A calcium score of zero excluded obstructive CAD in this cohort
f patientswith FH. Patientswith a calcium score of >400 exhibited
bstructive CAD in 69% (22/32).treatment +post treatment cholesterol×years of treatment).
g Scorebasedon thesumof theseverityofplaqueper segment (0% lumendiameter
stenosis = 0; >0–20%=1; >20–50%=2; >50–70%=3; >70%=4).
3.2.2. Coronary plaque analysis
After exclusion of 16 segments because of non-diagnostic image
quality 1918 segments were available for analysis. Sixty percent
(1144/1918) of the segments showed no signs of coronary artery
disease. In 4% (70/1918) of the segments a lesion of more thanFig. 1. Extent of coronary artery disease in relation to gender at different ages. CAD,
coronary artery disease.
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Fig. 2. Distribution of presence and severity of coronary plaque in the proximal, mid and distal segments of the coronary tree. LAD, left anterior descending coronary artery;
L distal
a es seg
i ; the d
(
k
s
s
m
(
(
3
(
p
b
c
(
t
n
3
m
(
m
l
r
s
3
o
wCX, left circumﬂex coronary artery; LM, left main; RCA, right coronary artery. The
rtery. The mid LAD includes segment 7 and the ﬁrst diagonal, the distal LAD includ
ntermediate branch; the mid LCX segment 13 and the ﬁrst marginal obtuse branch
Fig. 1). The CAD extent score was slightly higher in patients with a
nown LDL-mutation (10 (IQR 3–17) compared to patientswithout
uchmutation (6 (IQR 2–13)) although not signiﬁcantly (p=0.06). A
ub analysis in patients without (n=131) and with (n=9) diabetes
ellitus type II showed no signiﬁcant difference in calcium score
51 (2–346) vs. 89 (5–1580), respectively, p=0.57) and CAD extent
8 (3–16) vs. 5 (2–21), respectively, p=0.86).
.2.3. Plaque composition
Overall 54% (419/775) of the plaques were calciﬁed, 25%
192/775) were non-calciﬁed and 21% (163/775) were mixed. The
ercentage of calciﬁed plaques increased with increasing age in
othmen andwomen. Most non-calciﬁed plaques (146/192 (76%))
aused <20% lumen obstruction while the more severe plaques
>50% lumendiameter stenosis)weremainly causedby lesions con-
aining calcium (calciﬁed and mixed plaques) (60/70 (86%)). Of all
on-calciﬁed plaques 9 showed positive remodeling (9/192 (5%)).
.2.4. Distribution and localization of coronary plaque
The majority of the plaques were located in the proximal and
id-parts of the coronary arteries of which the proximal (99/140
71%)) part of the LAD showed plaque most frequently, while the
id-segment of the RCA showed the highest number of obstructive
esions (12/132 (9%)). The distal LCX showed the least atheroscle-
otic disease. The presence and the severity of CAD per coronary
egment are shown in Fig. 2.
.3. Risk scoresThemedian adjusted Framingham risk score in patientswithout
bstructive CAD (4 (1–10)) is signiﬁcantly lower than in patients
ith obstructive CAD (8 (5–12), p<0.001).RCA comprises segment 3, the posterior descending artery and the postero-lateral
ment 8 and the second diagonal. The proximal LCX comprises segment 11 and the
istal LCX includes segment 15 and the second obtuse marginal branch.
3.4. Follow up
Mean follow-up time was 29±8 months (range 9–43 months).
None of the patients died during the follow-up period, 2 patients
experienced stable AP, 1 patient suffered an ACS and one patient
had a positive exercise test without symptoms. All these 4 patients
underwent CABG. The 4 patients requiring CABG had a signiﬁcant
higher CAD extent (median 24 (IQR 22–31)) than patients without
a cardiac event (median CAD extent 7 (IQR 3–15), p<0.01) and they
all 4 exhibited obstructive CAD.
3.5. Relationship between patients characteristics and the CAD
extent
The results of the linear regression analysis are presented in
Table 2. The independent variables were gender (B −6.15, 95% CI
−9.35 to−2.89, p<0.01), treatedHDL-values (B−4.77, 95% CI−8.97
to−0.56, p=0.03), and treated LDL-values (B 1.48, 95%CI 0.25–2.61,
p=0.02).
The  statistics of the inter-observer agreement for the evalua-
tion of the stenosis severity per plaque and the plaque composition
were 0.78 and 0.83, respectively and of the intra-observer agree-
ment 0.81 and 0.84, respectively.
4. Discussion
FH is associated with an increased risk of adverse coronary
artery disease although some FH patients with this condition reach
ahigh agewithout signiﬁcant complications. Non-invasive CT coro-
nary plaque imaging is able to identify absence, presence and
extent of CAD and could be used as a tool to differentiate asymp-
tomatic patients with advanced CAD from those who are relatively
unaffected, and thereby guide preventive or therapeutic measures.
In our cross-sectional study of 140 asymptomatic statin treated
patientswithFHwe found that84%haddetectable coronaryplaque,
L.A. Neefjes et al. / Atherosclerosis 219 (2011) 721–727 725
Table 2
Predictive value of traditional risk factors for the CAD extent score per patient.a
n=140 Univariate linear regression Multivariate linear regression
B SE of B 95% CI p-Value B SE of B 95% CI p-Value
Age (years) 0.32 0.09 0.15–0.50 0.000 0.24 0.13 −0.17–0.498 0.068
Gender (female) −4.30 1.44 −7.14 to −1.45 0.003 −6.15 1.63 −9.35 to −2.89 0.000
Smokerb 0.99 1.57 −2.13–4.10 0.532
Diabetesb 0.65 2.90 −5.08–6.39 0.822
Hypertensionb 2.47 1.60 −0.69–5.64 0.125 – – – –
Positive family historyb −1.53 1.56 −4.61–1.55 0.327
Body mass index (kg/m2) 0.40 0.19 0.02–0.78 0.038 – – – –
Known genetic disorder −2.48 1.51 −5.47–0.51 0.103 – – – –
Total cholesterol-years score 0.02 0.01 0.01–0.03 0.001 0.02 0.01 −0.00–0.03 0.064
LDL-cholesterol (mmol/l) 1.23 0.56 0.13–2.32 0.029 1.48 0.56 0.25–2.61 0.018
HDL-cholesterol (mmol/l) −5.47 1.85 −9.12 to −1.82 0.004 −4.77 2.12 −8.97 to −0.56 0.027
Triglycerides (mmol/l) 0.35 0.48 −0.60–1.29 0.467
Tendon xanthomas 3.02 1.70 −0.34–6.38 0.077 – – – –
Variables in bold (p<0.2) were entered in the multivariate regression model. Backward elimination was used in the multivariate model (p<0.10). B, regression coefﬁcient;
CI, conﬁdence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SE, standard error.
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b Deﬁnition as in Table 1.
nd 24% had obstructive CAD (>50% diameter stenosis). Men exhib-
tedmore advanced coronary disease at a younger age thanwomen.
Only 20% of this FH cohort had a zero calcium score, which is
uch lower than the 44–51% shown in 3 large scale population
tudies, i.e. MESA [17], HNR [18] and Budoff et al. [2] or the 35–80%
f normal calcium scans in other asymptomatic populations [4,19].
otably a zero calcium score did not completely rule out presence
f CAD, because non-calciﬁed plaque was present in 4% of these
alcium free patients. However, none of these plaques caused >50%
uminal obstruction.
CTCA enables assessment of the total extent of coronary plaque
er patient, which provides a more comprehensive evaluation of
he coronary atherosclerosis than the assessment of the presence
f obstructive lesions alone. In addition it has been reported that
udden adverse coronary outcomes are usually caused by vulner-
ble plaques and that the severity of stenosis is of less importance
han the composition and the size of these plaques [20]. Min et al.
howedthatCTCAexaminationof theextentofCAD insymptomatic
atients, including a stenosis severity score which is largely com-
arable to our CAD extent score, is of incremental value to assess
ll cause death [21].
CTCA did not reveal any CAD in 16% of this cohort of patients
ith FH, which is within the range of the absence of CAD in 7–36%
symptomatic diabetic patients [6,7], but much lower than the
2–79% of other high risk asymptomatic patients [4,5]. In addition
e found obstructive CAD in 24% of our FH patients, although all
ere asymptomatic for CAD. In asymptomatic diabetic patients a
omparable prevalence has been described [6,7], but in other high
isk asymptomatic populations the prevalence of obstructive CAD
f approximately 5–16% was much lower [4,5].
Aprevious studybyMinameet al. [9] showeda lowerprevalence
f plaque (48%) in asymptomatic patientswith FH thanwe found in
ur current study (84%). Calcium score (0 (IQR 0–748)) and preva-
ence of obstructive CAD (19%) were only slightly lower. However,
he patient population ofMinameet al.was younger (45±13years)
han ours (52±8 years) and comprised 64% women compared to
6% women in our population. Additionally none of the patients
ere on statin treatment during the study, whereas only 66% had
een treated with statins previously.
Themajority of coronary plaqueswere localized in the proximal
nd mid parts of the coronary arteries which is largely similar to
he anatomical features of CAD in symptomatic patients. The prox-
mal LAD exhibited plaque in 80% of the patients whichmight be of
oncern because lesions in the proximal LAD were associated with
orse prognostic outcome [22].nosis = 0; >0–20%=1; >20–50%=2; >50–70%=3; >70%=4).
With increasing age in men and in women the percentage
of calciﬁed plaque increased and consequently the percentage
of non-calciﬁed plaques decreased. This is in line with other
CTCA studies in asymptomatic patients [4] and in symptomatic
patients [23] and it corresponds with the suggestion that the
advanced stages of coronary atherosclerosis are reﬂected by more
intense calciﬁcations [24]. There is still debate whether coronary
plaque calciﬁcation is associated with stability or instability of
a coronary plaque leading to coronary thrombosis. It has been
shown that plaques that have a low CT density (non-calciﬁed
lipid plaques) and evidence of positive remodeling were associ-
ated with a higher likelihood of adverse coronary events [23,25].
In our study we found positive remodeling in a small number of
non-calciﬁed plaques, but due to cross-talk of lumen attenuation
and absolute plaque density [26], we could not accurately dis-
tinguish between ﬁbrous and lipid tissue in those mainly small
plaques.
We demonstrated that gender, treated HDL-cholesterol and
treated LDL-cholesterol were signiﬁcantly associated with the
extent of CAD. Previously Junyent et al. also have shown the strong
independent predictive value of HDL-cholesterol levels (nega-
tively) for preclinical carotid atherosclerosis in patients with FH.
Our results therefore conﬁrm their suggested important role for
HDL-raising therapies in future treatment strategies in patients
with FH [27].
It has been shown that traditional risk factors do play an impor-
tant role in patients with FH but the predictive value might be
different than in the general population [28]. However, we could
not conﬁrm a signiﬁcant relation between the traditional risk fac-
tors age, smoking, hypertension, diabetes or the speciﬁc FH related
presence of tendon xanthomas or presence of a LDL-receptormuta-
tion and the extent of CAD. This was probably the result of the
limitednumberofpatientswithFH thatwere studied causing insuf-
ﬁcient statistical power.
Nine patientswith diabetesmellitus type 2were included in our
study and these patients may have a more extensive expression of
CAD. However, a separate analysis of the patients with diabetes
mellitus type 2 compared to patients without diabetes did not
reveal a difference in extent of CAD.
Using an adjusted Framingham Risk Score we could demon-
strate that there was a direct relation between the Framingham
Risk Score and the presence of obstructive CAD. The FRS has been
based on a general population and patients with FH were not
enough represented in that study. Nevertheless, although the FRS
in our population might underestimate the total 10-year CHD risk,
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t shows the positive relation between the risk factors and the CAD
xtent.
As has been recently reported by Hadamitzky et al. cardiac CT
as incremental prognostic value in asymptomatic individuals [19].
n our study though, there was a low incidence of cardiac events
uring29months follow-up.We foundahigher extentofCAD in the
atients that developed stable angina or acute coronary syndrome
ollowed by CABG during FU than in patients without development
f clinical symptoms of CAD. Additional studies are warranted to
stablish whether it is reasonable to intensify medical preventive
reatment in patients with evident CAD on CT to prevent progres-
ion of disease and development of adverse events and to continue
r even lower current medical treatment in patients without sub-
linical coronary atherosclerosis on CT. Cardiac CT might lead to a
ore cost-effective allocation of preventive efforts.
Radiation exposure of CT coronary angiography remains a mat-
er of concern. By using a dual source scanner with optimized scan
rotocols the mean estimated effective dose of a CTCA in our study
as 7.9mSv. To minimize the lifetime attributable risk of cancer
nd in women the risk of birth abnormalities in their offspring
e included only women of at least 45 years and men of at least
0 years of age. However, due to recent technical improvements
he effective radiation dose of a CTCA currently can be <3.0mSv
29]. Decreasing the radiation dose is of positive inﬂuence on the
arm–beneﬁt ratio of CTCA,whichmight even induce extendeduse
f CTCA for screening purposes or repetitive scanning for CAD pro-
ression follow up when CT-scanning below 1mSv is deﬁnitively
vailable.
.1. Limitations
CTCAmaynotbeable todetect veryearly coronaryatherosclero-
iswhich is beyond the spatial resolution of current CT-technology.
TCA tends to overestimate or underestimate the severity of
bstructive CAD and in particular calciﬁed plaques hinder precise
everity assessment, due to blooming effects. In patientswith a cal-
ium score >10 (Agatston) and more explicit >400, the diagnostic
ccuracy of CTCA to exclude or detect obstructive CAD is hampered
ompared to patients with less calcium [30]. Our patients with FH
ere treated with intense lipid lowering drugs which will have
odiﬁed the natural history of plaque progression. We included
nly patients aged 40–70 years old that may have affected the
revalence of CAD considering the strong relation of age andCAD in
he elderly. However we sought to include patients in whom addi-
ional long lasting measures to prevent progression of CAD could
e beneﬁcial.
. Conclusion
CT coronary imaging uniquely allows for non-invasive assess-
ent of the extent, severity, anatomic distribution and plaque
omposition of coronary artery disease in asymptomatic patients
ith FH. The extent of CAD in this high risk population is related
o lipid blood values and ranges from absence of detectable CAD
n less than one out of six patients to obstructive CAD in nearly a
uarter of patients despite the absence of symptoms. The anatom-
cal distribution and composition of coronary plaques is similar to
hat of patients without FH.
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